Capital International Sarl Portfolio holdings
Top Buys
| 1 |
AstraZeneca
AZN
|
+$176M |
| 2 |
NVIDIA
NVDA
|
+$61.1M |
| 3 |
Alphabet (Google) Class A
GOOGL
|
+$42.5M |
| 4 |
Amphenol
APH
|
+$36.1M |
| 5 |
Royalty Pharma
RPRX
|
+$22.5M |
Top Sells
| 1 |
Synopsys
SNPS
|
+$40.6M |
| 2 |
Flutter Entertainment
FLUT
|
+$28.8M |
| 3 |
Broadcom
AVGO
|
+$23.6M |
| 4 |
Alnylam Pharmaceuticals
ALNY
|
+$22.5M |
| 5 |
Ecolab
ECL
|
+$21.8M |
Sector Composition
| 1 | Technology | 24.91% |
| 2 | Healthcare | 15.18% |
| 3 | Consumer Discretionary | 13.77% |
| 4 | Communication Services | 11.89% |
| 5 | Industrials | 10.75% |
Similar funds
Capital International Sarl's Q1 2026 Portfolio in Review
As of Q1 2026, Capital International Sarl held 330 positions worth $6.11B, down 1.9% from $6.23B the previous quarter. Its ten largest holdings account for 34% of the portfolio.
Capital International Sarl deployed $247M of net new capital in Q1 2026, opening 30 new positions and adding to 139 existing holdings. Its largest new stake was AstraZeneca: 914,752 shares worth $178M.
By sector, the portfolio is most concentrated in Technology at 25% of assets, down from 27% a quarter earlier, followed by Healthcare and Consumer Discretionary.
On the sell side, the largest reduction was Broadcom, an estimated $23.6M trimmed.
- Capital International Sarl's largest Q1 2026 buy was AstraZeneca: 914,752 shares worth $178M.
- Capital International Sarl added most to NVIDIA in Q1 2026, an estimated $61.1M increase.
- Capital International Sarl's biggest Q1 2026 reduction was Broadcom, cutting an estimated $23.6M.
- Capital International Sarl fully exited Synopsys in Q1 2026, selling an estimated $40.6M.
- Capital International Sarl's ten largest holdings make up 34% of its $6.11B portfolio in Q1 2026.
- Capital International Sarl opened 30 new positions and closed 43 in Q1 2026.
- Capital International Sarl's portfolio value fell 1.9% quarter-over-quarter to $6.11B.
Based on Capital International Sarl's 13F filing for Q1 2026, filed 13 May 2026.